Halozyme Therapeutics (HALO) Tops Q4 EPS by 3c; Guides FY15 Revs

Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.04), $0.03 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $30.38 million versus the consensus estimate of $25.6 million.

Halozyme Therapeutics sees FY2015 EPS of $85.00-$95.00, versus the consensus of $97.70.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Apple’s big price hike seen as "an unprecedented push to protect margins"
• Orion Digital receives Nasdaq minimum bid price deficiency notice